Conflict of interest statement: Conflicts of Interest RS has served as a study 
investigator and a consultant for Janssen Alzheimer Immunotherapy Research & 
Development, LLC, and for Pfizer Inc., and has received honoraria for 
participation in symposiums. She has also served as a consultant and/or site 
investigator for Bristol-Myers-Squibb, Roche, Elan, Biogen-IDEC, Avid, and 
Bayer. SS has served as a consultant and study investigator for Janssen 
Alzheimer Immunotherapy Research & Development, LLC., Pfizer Inc., and Elan 
Corporation, plc. phase 2 and 3 studies of bapineuzumab. DB reports no conflicts 
of interest. DT provides review of MRI images for Janssen Alzheimer 
Immunotherapy Research & Development, LLC. JB serves as a neuroradiological 
consultant to SYNARC Inc., an imaging contract research organization contracted 
by both sponsor companies (Janssen Alzheimer Immunotherapy Research & 
Development, LLC. and Pfizer Inc.); he also serves as a consultant to Janssen 
Alzheimer Immunotherapy Research & Development, LLC. for non-clinical research 
activities. NF has provided consulting and/or image analysis services to Elan 
Corporation, plc., Janssen Alzheimer Immunotherapy Research & Development, LLC., 
Pfizer Inc., and Wyeth Pharmaceuticals as well as to AstraZeneca, Bristol-Myers 
Squibb, Eli Lilly and Company, GE Healthcare, Lundbeck A/S, and IXICO. MR serves 
as consultant to Janssen Alzheimer Immunotherapy Research & Development, LLC. MS 
participates in a consulting/advisory capacity for Eli Lilly and Company, 
Amerisciences, Takeda Pharmaceuticals Inc., Eisai Co., Ltd., Pfizer Inc., and 
GlaxoSmithKline plc. and receives royalties from Wiley and AmeriSciences, LP. He 
receives contracting fees/grants from Celgene Corporation, Ceregene, Inc., Bayer 
AG, Baxter International Inc., Bristol-Myers Squibb, Eli Lilly and Company, 
Pfizer Inc., Janssen Alzheimer Immunotherapy Research & Development, LLC., Avid 
Radiopharmaceuticals, Inc., Genentech, Inc. and Eisai Co., Ltd. LH serves on the 
study steering committee and has acted as a consultant for Janssen Alzheimer 
Immunotherapy Research & Development, LLC., but receives less than $10,000 
annually for such consulting activities. AP has received grant/research support 
from Baxter International Inc., Bristol-Myers Squibb, Eisai Co., Ltd., Elan 
Corporation, plc., Genentech, Inc./ Hoffmann-La Roche Inc., Janssen Alzheimer 
Immunotherapy Research & Development, LLC., Medivation, Inc., Pfizer Inc., and 
Toyama Chemical Co., Ltd. He has also served as a consultant/participated on 
advisory boards for Elan Corporation, plc., Janssen Alzheimer Immunotherapy 
Research & Development, LLC., Medivation, Inc., Pfizer Inc., Transition 
Therapeutics Inc., and Toyama Chemical Co., Ltd.. He is also a member of the 
speakers’ bureau for Forest Laboratories, Inc. IL is a stockholder in Elan 
Corporation, plc. RB is an employee of and receives stock and stock options from 
Pfizer Inc. MA, KM, YL, EL, KG, RHB, and GK are employees of Janssen Alzheimer 
Immunotherapy Research & Development, LLC. MG is a consultant to Janssen 
Alzheimer Immunotherapy Research & Development, LLC. and is a stockholder in 
Elan Corporation, plc.